Following successful use of FMX314 in general surgery, the platform for single-port laparoscopy has now been employed in several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform for other surgical applications, according to Fortimedix Surgical.

FMX314 is a single-port surgery platform that is compatible with a standard 15mm laparoscopic trocar, promising fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis. A procedure with the platform closely mimics conventional, multi-port laparoscopy.

Market introduction of FMX314 in the United States for abdominal laparoscopic surgery is expected in the fourth quarter of this year, followed by commercial launch in Europe. The FMX314 surgical platform is an investigational device and not available for sale.

Fortimedix Surgical is headquartered in Nuth in the Netherlands and has a US subsidiary in San Diego, CA.